SAVANNAH, Georgia — There’s no medical treatment for Charcot-Marie-Tooth (CMT) disease, a debilitating neurologic disorder that’s both progressive and incurable. But now, nerve specialists ...

and an estimated one million individuals with an inherited degenerative nerve condition called Charcot–Marie–Tooth disease type 2 (CMT2). Peripheral neuropathy can cause severe disability and ...

Other laboratory tests to confirm the condition. Treatments can help manage condition, no known cure Diagnosed by medical professional Requires lab test or imaging A lifelong condition Certain ...

In light of those characteristics, Cellatoz is applying NRPCs, in the form of CLZ-2002, to the treatment of Charcot–Marie–Tooth (CMT) type 1A disease and other health conditions caused by ...

Other laboratory tests to confirm the condition. Treatments can help manage condition, no known cure Diagnosed by medical professional Requires lab test or imaging A lifelong condition Certain ...

Miralinc Pharma Inc. has patented new heterocyclic selective histone deacetylase 6 (HDAC6) inhibitors reported to be useful for the treatment of type 2 Charcot-Marie-Tooth disease and ...

Mitochondria In Motion Inc. has identified new N-(trans-4-hydroxycyclohexyl)-6-phenylhexanamide derivatives acting as mitofusin activators and reported to be useful for the treatment of Alzheimer’s, ...

Avicenna received a patent covering ROCK inhibitor compounds for ALS, Parkinson’s, and other neurodegenerative conditions.

Charcot-Marie-Tooth affects 1 in 2,500 people or approximately 2.6 million people worldwide. The disease causes progressive nerve damage and those with CMT ... Severe, chronic pain is common.

An east Auckland teenager with a rare genetic condition is grateful for having received equipment that will make it easier ...

With a history of spinal injury and having not undergone a surgical stabilization, a syrinx was suspected. A magnetic resonance imaging (MRI) study of the patient's cervical and thoracic spine was ...

Actio is advancing two lead rare disease programs with first-in-class potential for the treatment of Charcot-Marie-Tooth Disease, Type 2C (CMT2C) and genetic epilepsy. The CMT2C program is ...